STAT-Dx unveils new molecular diagnostics platform

23 April 2017 (Last Updated April 23rd, 2017 18:30)

Spanish diagnostic solutions provider STAT-Dx is set to unveil its new in-vitro diagnostics system DiagCORE at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Vienna, Austria, between 22 and 25 April.

Spanish diagnostic solutions provider STAT-Dx is set to unveil its new in-vitro diagnostics system DiagCORE at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Vienna, Austria, between 22 and 25 April.

DiagCORE is a fully integrated multiplex real-time polymerase chain reaction (PCR) diagnosis platform with the potential to detect approximately 48 molecular targets simultaneously in a single sample.

The multiplex real-time PCR capability makes the system ideal for complex assays from all types of clinical samples.

STAT-Dx chief executive officer Jordi Carrera said: "We are delighted to be unveiling our DiagCORE system and first respiratory panel at ECCMID.

"STAT-Dx's fast, syndromic diagnostic system is set to become a key asset in the infectious diseases diagnostic market, which is rapidly embracing innovative multiplex PCR-based technologies.

"DiagCORE's simplicity and delivery of fast actionable answers has the potential to greatly improve clinical and economic outcomes. Furthermore, with low manufacturing costs at the core of our design, we are confident on being able to bring a highly competitive product to the market."

"With low manufacturing costs at the core of our design, we are confident on being able to bring a highly competitive product to the market."

DiagCORE Respiratory Panel is the firm's first assay, with the capability to simultaneously detect and identify around 22 viral and bacterial pathogens.

The test can be used with nasopharyngeal swab samples from patients with acute respiratory symptoms.

STAT-Dx intends to commence registration trials for the respiratory panel, with plans to receive CE mark in the second half of this year.

The firm is also working on additional panels for clinical microbiology and infectious disease applications and expects to commercialise its second assay, Gastrointestinal Panel, next year.